Tamoxifen metabolism and efficacy in breast cancer- a prospective multicentre trial
2018
Purpose: Levels of
endoxifen, the most active metabolite of
tamoxifen, vary by the highly polymorphic cytochrome P450 (CYP) 2D6 enzyme. We prospectively investigated
tamoxifenefficacy by serum
endoxifenlevels and the
tamoxifenactivity score (TAS). Experimental Design: A prospective observational multicenter study included postmenopausal women with an estrogen receptor–positive breast cancer receiving first-line
tamoxifen, 20 mg daily in the neoadjuvant or metastatic setting, recruited between February 2009 and May 2014. The primary endpoint was the objective response rate (ORR) using RECIST criteria 1.0. Secondary endpoints were clinical benefit (CB), progression-free survival (PFS), and tolerability of
tamoxifen. The main analysis used logistic regression to relate ORR to serum
endoxifenlevels after 3 months. Endpoints were also related to other
tamoxifenmetabolites and to TAS. Results:
Endoxifenlevels were available for 247 of all 297 patients (83%), of which 209 with
target lesions(85%). Median follow-up time for PFS was 32.5 months, and 62% progressed. ORR and CB were 45% and 84%, respectively. ORR was not related to
endoxifen, and the OR of ORR was 1.008 per μg/L increase in
endoxifen(95% confidence interval, 0.971–1.046; P = 0.56 ). In general, none of the endpoints was associated with
endoxifenlevels,
tamoxifenmetabolites, or TAS. Conclusions: Under the prespecified assumptions, the results from this prospective clinical trial do not suggest
therapeutic drug monitoringof
endoxifento be of clinical value in postmenopausal women treated with
tamoxifenfor breast cancer in the neoadjuvant or metastatic setting. Clin Cancer Res; 24(10); 2312–8. ©2018 AACR .
Keywords:
-
Correction
-
Source
-
Cite
-
Save
37
References
33
Citations
NaN
KQI